Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM, BSE: 507789) is a Gurugram, Haryana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,429 Cr, it ranks #1,413 by market cap among the 6,197 Indian listed companies on FinBizNet, and #22 of 63 in Pharmaceuticals. At ₹216.30 (as of 16 Nov 2026), the share price is 18.2% below its 52-week high of ₹264.50 and 39.5% above its 52-week low of ₹155.00. The share price is up 0.1% over one year and down 6.0% over three months.
| Current Price | ₹216.30 |
|---|---|
| Market Cap | ₹1,429 Cr |
| NSE Symbol | JAGSNPHARM |
| BSE Code | 507789 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 34.6 |
| Return on Equity | 16.69% |
| Return on Assets | 10.22% |
| 52-Week Range | ₹155.00 – ₹264.50 |
| 1-Year Price Change | +0.1% |
| 3-Month Price Change | -6.0% |
| Beta (1Y) | 0.23 |
| Dividend Yield | 1.15% |
| Headquarters | Gurugram, Haryana |
| Website | www.jagsonpal.com |
| Revenue | ₹96 Cr |
|---|---|
| Net Profit | ₹12 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹1.86 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 68.81% of Jagsonpal Pharmaceuticals Limited's shares as of Sept 2026, against 67.54% in Sept 2025 (+1.27 percentage points). Delivery averaged 49.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
1. Pharmaceuticals-This segment manufactures and sells pharmaceuticals and intermediate drugs.
1. Manufacturing and Trading of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Jagsonpal Pharmaceuticals Limited | ₹1,429 Cr | 34.6 | 16.69% | ₹96 Cr | +0.1% |
Listed by market capitalisation. Ratios are shown for context only.
Jagsonpal Pharmaceuticals Limited is trading at ₹216.30, with a market capitalisation of ₹1,429 Cr.
Jagsonpal Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Jagsonpal Pharmaceuticals Limited has a P/E of 34.6 and a return on equity of 16.69%.
Jagsonpal Pharmaceuticals Limited is listed on the NSE under the symbol JAGSNPHARM and on the BSE under the scrip code 507789.
Jagsonpal Pharmaceuticals Limited's share price is up 0.1% over one year and down 6.0% over three months. Its 52-week range is ₹155.00 to ₹264.50.
In Q2 FY27, Jagsonpal Pharmaceuticals Limited reported revenue of ₹96 Cr and net profit of ₹12 Cr, with basic EPS of ₹1.86 (consolidated, parsed from the company's exchange filing).
Promoters held 68.81% of Jagsonpal Pharmaceuticals Limited's shares as of Sept 2026, against 67.54% in Sept 2025 (+1.27 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.